|Day Low/High||2.90 / 3.20|
|52 Wk Low/High||1.46 / 3.88|
Five Additional Presentations to Highlight the Company's Cellular Immunotherapy Programs
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CTRN, FSFG, LWAY Downgrades: BAM, BT, DHT, RFIL, SNP Initiations: FATE Read on to get TheStreet Quant Ratings' detailed report:
Phase 1/2 Clinical Trial of ProTmune for Prevention of Acute GvHD and CMV Infection Now Open for Enrollment
These stocks look ready to break out and trade higher from current levels.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.